Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-masked, Placebo-controlled Safety, Tolerability, and Efficacy Study of VRDN-001, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Participants With Chronic Thyroid Eye Disease (TED)

NCT06021054 is registered in ClinicalTrials.gov with Viridian Therapeutics, Inc. as lead sponsor.

NCT NCT06021054
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06021054 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-masked, Placebo-controlled Safety, Tolerability, and Efficacy Study of VRDN-001, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Participants With Chronic Thyroid Eye Disease (TED)
Lead sponsor
Viridian Therapeutics, Inc.
Phase
Phase 3
Overall status
Completed
Start date
November 1, 2023
Completion date
July 25, 2025
Enrollment
188 (actual)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

thyroid eye disease